ZA951088B - Use of substituted arylcyclobutylalkylamine compounds in the treatment of seizures neurological disorders and neurological damage - Google Patents

Use of substituted arylcyclobutylalkylamine compounds in the treatment of seizures neurological disorders and neurological damage

Info

Publication number
ZA951088B
ZA951088B ZA951088A ZA951088A ZA951088B ZA 951088 B ZA951088 B ZA 951088B ZA 951088 A ZA951088 A ZA 951088A ZA 951088 A ZA951088 A ZA 951088A ZA 951088 B ZA951088 B ZA 951088B
Authority
ZA
South Africa
Prior art keywords
neurological
arylcyclobutylalkylamine
seizures
substituted
compounds
Prior art date
Application number
ZA951088A
Inventor
William Roger Buckett
Original Assignee
Boots Co Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boots Co Plc filed Critical Boots Co Plc
Publication of ZA951088B publication Critical patent/ZA951088B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA951088A 1994-02-11 1995-02-10 Use of substituted arylcyclobutylalkylamine compounds in the treatment of seizures neurological disorders and neurological damage ZA951088B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9402641A GB9402641D0 (en) 1994-02-11 1994-02-11 Therapeutic agents

Publications (1)

Publication Number Publication Date
ZA951088B true ZA951088B (en) 1996-01-23

Family

ID=10750231

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA951088A ZA951088B (en) 1994-02-11 1995-02-10 Use of substituted arylcyclobutylalkylamine compounds in the treatment of seizures neurological disorders and neurological damage

Country Status (5)

Country Link
AU (1) AU1578295A (en)
GB (1) GB9402641D0 (en)
IL (1) IL112602A0 (en)
WO (1) WO1995021615A1 (en)
ZA (1) ZA951088B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
AU2007200334B8 (en) * 1998-08-24 2010-10-21 Sepracor, Inc. Methods of using and compositions comprising dopamine reuptake inhibitors
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6288125B1 (en) * 2000-03-17 2001-09-11 Knoll Pharmaceuticals Company Treatment of hiatial hernia
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
KR20060080817A (en) 2005-01-06 2006-07-11 씨제이 주식회사 A dicarboxylic acid salt of sibutramine
KR20060080818A (en) 2005-01-06 2006-07-11 씨제이 주식회사 A sulphonic acid salt of sibutramine
EP1846359A4 (en) * 2005-01-06 2010-03-31 Cj Cheiljedang Corp Inorganic acid salts of sibutramine
CN102786444A (en) * 2012-07-24 2012-11-21 上海瑞博化学有限公司 Preparation method for sulfonates of sibutramine analogues

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3526656A (en) * 1967-05-25 1970-09-01 Parke Davis & Co (1-arylcyclobutyl)carbonyl carbamic acid derivatives
JP2675573B2 (en) * 1988-03-31 1997-11-12 科研製薬株式会社 Brain function improver
AU4542893A (en) * 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine

Also Published As

Publication number Publication date
AU1578295A (en) 1995-08-29
GB9402641D0 (en) 1994-04-06
WO1995021615A1 (en) 1995-08-17
IL112602A0 (en) 1995-12-08

Similar Documents

Publication Publication Date Title
IL133800A0 (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
HUP0100069A3 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
HUP9800033A3 (en) Compositions for the treatment of dermatological disorders and methods for their use
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
HK1042475A1 (en) Substituted thiazoles for the treatment of inflammation
EP0776210A4 (en) A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
EP0924983A4 (en) S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
AU3339897A (en) Sulphonamide derivatives and their use in the treatment of cns disorders
SI0781136T1 (en) Compounds and methods for the treatment of cancer
PL339425A1 (en) Treatment of behavioural disorders
HUP9900508A3 (en) Use of 4-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene for prophylaxis and treatment of sequelae of reduced circulation in the brain and neurodegenerative disorders
ZA951088B (en) Use of substituted arylcyclobutylalkylamine compounds in the treatment of seizures neurological disorders and neurological damage
AU2466695A (en) The use of famotidine and related compounds in the treatment of movement disorders
IL136110A0 (en) Methods and compositions for the treatment of psoriasis
IL115664A0 (en) Treatment of disorders with duloxetine
PL332313A1 (en) Application of benzopyranoles in treatment of neurological disorders
PL345110A1 (en) Aza-heterocyclic compounds used to treat neurological disorders and hair loss
GR3033646T3 (en) The use of buckminsterfullerene for treatment of neurotoxic injury
ZA958558B (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
IL129460A0 (en) Use of lofexidine in the treatment of behavioral disorders
GB9518887D0 (en) Treatment of muscular disorders
HUP9902802A3 (en) Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
GB9415901D0 (en) Novel compounds and treatment
EP0893123A4 (en) Agent for use in the prevention and treatment of disorders associated with various types of ageing